Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Worldcrunch on MSN7h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?
That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Needham downgrades Biogen on slow growth of Alzheimer's drug
Investing.com - Needham downgraded Biogen Inc (NASDAQ: BIIB) on Monday, citing slower-than-expected growth for its ...
Fintel on MSN8h
Needham Downgrades Biogen (BIIB)
Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.
Biogen downgraded to Hold from Buy at Needham
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
Yahoo Finance12h
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...
Business Insider19h
Needham downgrades Biogen (BIIB) to a Hold
Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company’s shares closed last Friday at $159.99. Don't Miss our Black Friday Offers: ...
ETF Daily News23h
Biogen (NASDAQ:BIIB) Price Target Raised to $300.00
Biogen (NASDAQ:BIIB – Free Report ... and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM ...